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The prevalence of pre-diabetes is increasing worldwide and may start 7 to 10 years before the clinical diagnosis of
diabetes. In this stage the presence and accumulation of risk factors is common and already implies an increase in
cardiovascular risk. Likewise, the onset of cardiovascular diseases (CVD), mainly coronary artery disease (CAD), per-
ipheral vascular disease and cerebrovascular disease can also take place, all of which account for high rates of mor-
bidity and mortality worldwide. Considering pre-diabetes as a clinical entity, non-pharmacological and
pharmacological treatments are indicated with drugs which have shown clinical benefits related to reduction in
morbidity and mortality. However, there is still need for new long-term studies to assess the real benefits of several
new therapeutical approaches, as well as its cost-effectiveness.
Introduction
The natural history of type 2 diabetes has been studied
in many populations and it has been described as a rela-
tionship among a genetic susceptibility, obesity and phy-
sical inactivity.
Both obesity and physical inactivity result in insulin
resistance states, which in turn will stress beta cell to
increase insulin secretion Beta cell dysfunction - it is
considered an important early pathophysiologic defect
in diabetes type 2 and it is present since the pre-dia-
betes phase [1]. This fact had been confirmed in a
study, which performed autopsies in normal individuals,
glucose intolerant and patients with diabetes showed
that even during pre-diabetes phase there is a loss of
beta cell function up to 50% due apoptosis [2]. However
according to Prof De Fronzo the loss of beta cell func-
tion could be even more, up to 50% [1].
Nowadays the treatment of type 2 diabetes must
address the core of pathophisiologic defects of the dis-
ease which means that we have to treat both beta cell
dysfunction and insulin resistance as soon as we have
the diagnosis of diabetes, and perhaps as early as we
have the diagnosis of glucose intolerance [1]. However,
the slow increase in glyceamic levels - currently referred
to as dysglicaemia - causes considerable delay in both
diagnosis and consequently the beginning of the treat-
ment. Nonetheless, during this phase, some underlying
mechanisms common to micro and macrovascular com-
plications, like endothelial dysfunction and oxidative
stress, are already present [3]. Nowadays the continuous
relationship between blood glucose and cardiovascular
disease (mortality and morbidity) and the development
of diabetes type 2 is a matter of concern and will be dis-
cussed in another section of the present review.
In 1979, the National Diabetes Data Group proposed
that the diagnosis of diabetes should be established
when fasting dysglicaemia levels were ≥ 140 mg/dL, and
stated the condition of impaired tolerance to glucose
(IGT) in those individuals submitted to OGTT present-
ing dysglicaemia elevation levels that ranged from ≥ 140
to <200 mg/dL 2 hours after the ingestion of dextrosol
[4].
The values for diagnosing diabetes through fasting
glucose have progressively changed by decreasing its
value to ≥ 126 mg/dL. Another pre-diabetic condition
can be diagnosed when fasting glucose is between 100
to 126 mg/dL and it has presently been named as
impaired fasting glucose (IFG).
IGT and IFG, therefore, represent intermediate states
of abnormal dysglicaemia and both conditions are
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last up to seven years in those who develop diabetes.
However, a third of individuals may not progress at all
and indeed a third could revert back to normal [6]. It
has been estimated that, by the year of 2025, the num-
ber of people with pre-diabetes will be 472 millions [6].
Data from the World Health organization (WHO) and
American Diabetes Association (ADA) estimated that
around 27% of individuals with normal fasting glucose
migrated to pre-diabetes and 8% to diabetes when sub-
mitted to oral glucose tolerance test (OGTT) and, more-
over, 50% of subjects with dysglicemia develop diabetes
[7].
The development of chronic complications of diabetes,
either micro or macrovascular, can begin earlier in the
pre-diabetes phase as demonstrated by UKPDS and
DPP, with increasing prevalence from IFG to IGT [8,9].
The highest prevalence is observed in patients with both
conditions [10]. Decreased level of HDL-cholesterol,
increased level of LDL-cholesterol, triglycerides and
hypertension, are present more frequently among pre-
diabetic individual, increasing the cardiovascular risk
[11]. Therefore, the identification of individuals with
high risk for pre-diabetes must be emphasized. Some
risk factors like gestational diabetes, hyperuricemia, cer-
ebrovascular disease, peripheral disease of lower limbs,
ischemic cardiopathy and polycystic ovary syndrome in
women with BMI ≥ 25 kg/m
2 must be added to the
above-mentioned. It is important to take note of the
fact that many drugs have shown unfavorable effects on
glucose metabolism and could induce dysdysglicaemia.
Among these, antihypertensive drugs, such as betablock-
ers and thiazidic diuretics, stand out. These drugs are
widely used and recommended as first-line medications
for treating hypertension [12]. It is important to high-
light that such recommendations are supported by evi-
dence from several clinical trials. For patients with
ischemic cardiopathy, the use of beta-blocker is compul-
sory [12].
However, in modern times, the choice of antihyper-
tensive drugs has taken into account its metabolic neu-
trality in addition to its effectiveness and efficacy, and
for this reason, angiotensin receptor blockers (ARBs),
angiotensin-converting enzyme inhibitors (ACE inhibi-
t o r s )a n dc a l c i u mc h a n n e lb l o c k e r s( C C B s ) ,e i t h e ri s o -
lated or in association, have been increasingly used [13].
Concerning physiopathology, individuals with isolated
IFG predominantly present hepatic insulin resistance,
with normal muscle insulin resistance. The beta-cell
function is impaired, with a decrease in the secretory
insulin response in pool 1 (0 to 10 minutes), and pool 2
presents reduction in response at the initial stage (first
30 minutes); but at the late stage (60 to 120 minutes),
this response becomes normal. However, patients with
isolated IGT present normal or fairly decreased hepatic
insulin sensitivity, but moderate or severe muscle resis-
tance to the action of insulin. The beta cell presents a
similar flaw, as observed in IFG patients of pool 1, i.e.,
decrease in insulin secretion from 0 to 10 minutes, how-
ever, with a severe insulin secretion deficit at the early
stage of pool 2 [14].
Dysglicaemia and cardiovascular disease
There is a strong relationship between dysglicaemia and
cardiomorbidity and cardiomortality
Cardiomorbidity
There is a relationship between dysglicaemia and cardio-
vascular atherosclerotic disease as certified by several
clinical trials which have demonstrated the association
of pre-diabetes with subclinical indicators of athero-
sclerosis, as described bellow:
1. Calcium score of coronary arteries: the average
score of coronary calcification (CAC) in pre-diabetic
patients is about 6.7 times increased (93 vs. 14) com-
pared to non-diabetic individuals [15];
2. Carotid intima-media thickness: the results from
the Mexico City Diabetes Study have shown that the
relation of the thickness between the intima and the
medium in the common and internal carotid
arteries, were significantly more elevated in pre-dia-
betics as compared to non-diabetics [16]. European
[17] and Indian studies [18] also showed the same
event after adjustments to other risk factors;
3. Prevalence of cardiovascular disease: in pre-dia-
betics, even without metabolic syndrome, there is an
increased incidence both in coronary artery disease
and myocardial infarction. In patients with metabolic
syndrome, such morbidities occur at a higher level,
and they also present higher incidence of stroke [19];
4. Hypertension: the Framinghan study demon-
strated that, for both genders, the cardiovascular
event rate has been progressively increasing from the
normal levels of arterial pressure. In individuals with
glucose intolerance, such events also occur, though
at a much higher rate, proportionally to the arterial
pressure level [20];
5. Worsening of the clinical evolution of acute cor-
onary syndromes: the Glucose Tolerance in Patients
with Myocardial Infarction (GAMI) study [21]. Such
study, performed with subjects with acute myocar-
dial infarction, showed that only 34% of patients had
normal dysglicaemia upon admittance, against 35%
and 31% of pre-diabetics and diabetics, respectively.
The same was observed in two other studies, the
China Heart Study (CHS) [22]and the Euro Heart
Survey (EHS), for which only 36% and 45% of indivi-
duals, respectively, had normal fasting dysglicaemia
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the great majority already presented a change in glu-
cose metabolism upon admittance and were unaware
of such condition;
6. Several studies have demonstrated that other bio-
chemical markers of cardiovascular disease such as
C-reactive protein, tumour necrosis factor-alpha
increase in graded manner with deterioration of glu-
cose intolerance [23];
Cardiomortality
Studies have demonstrated the increase in the mortality
rate from normal to pre-diabetic and to diabetic indivi-
duals.
1. Data from the Funagata Diabetes Study through
seven years of follow-up showed that the cumulative
survival rate decreases in pre-diabetics at an inter-
mediate level between normoglycaemic and diabetic
[24];
2. The Second National Health and Nutrition Exami-
nation Survey Mortality Study (NHANES 2), showed
an increase both in cardiovascular and in total mor-
tality rates, and the latter was over 40%, while com-
paring normoglycaemic with glucose intolerant
patients [25];
3. The Collaborative Analysis of Diagnostic Criteria
in Europe (DECODE), covered a broader spectrum
of dysglicaemia and presents data which showed that
the rate of cardiovascular death risk increases in
both forms of pre-diabetes, though it is higher in
IGT versus IFG [10];
4 .T h eG A M Is t u d ys h o w e dt h a tt h ef r e es u r v i v a l
period of events during 50 months was significantly
shorter for individuals with dysglicaemia when com-
pared to normoglycemic patients [20];
5. The EHS observed that the free survival period
c u r v eo fe v e n t sf o ri n d i v i d u a l sw h op r e s e n t e da
change in glucose metabolism (impaired tolerance,
recent diabetes and known diabetes) was also shorter
when compared to patients with normal dysglicae-
mia and, again, the presence of diabetes caused a
worse prognosis with survival period reduction, i.e.,
the longer the disease period and the more advanced
its clinical stage, the shorter the cardiovascular survi-
val period [17];
6. In conclusion, both studies (GAMI and EHS)
showed that dysglicaemia was common in patients
with coronary artery disease and it was related to a
worse clinical evolution and a higher risk of other
events and death.
7. The China Heart Study evaluated the relationship
of dysglicaemia and the CV risk in the Asian popula-
tion [22]. It is known that Asian populations present
a difference in body fat distribution compared to
Caucasians and several metabolic changes, particu-
larly when they aggregate and compose the risk fac-
tors for metabolic syndrome, related to visceral fat.
Thus, for such study, patients hospitalized with cor-
onary artery disease, both acute and chronical, were
randomized and allocated. Type 1 diabetes patients
were excluded, and patients who had not been diag-
nosed with type 2 diabetes had taken the oral glu-
cose tolerance test. Results showed that, in this
population sample, 2/3 of patients had previous
undiagnosed dysglicaemia. Currently, 80% of the
individuals would have remained undiagnosed if the
fasting dysglicaemia (FG) had been performed alone.
Thus, similarly to the studies mentioned previously,
for those individuals, fasting dysglicaemia did not
reflect the real clinical setting with regards to glu-
cose homeostasis [22]. In conclusion, CHS demon-
strated that type 2 diabetes and pre-diabetes were
also found in Asian populations with coronary artery
disease, that such condition would not have been
diagnosed if FPG had been performed alone and
that 80% or more of those patients would have
remained undiagnosed if they had not taken the
OGTT.
Considering the above-mentioned data, the develop-
ment of “guidelines” with recommendations for handling
diabetes, pre-diabetes and CVD was performed.
The algorithm recommended by the European Society
of Cardiology and by the European Association for the
Study of Diabetes determines the selection of individuals
in two initial groups, according to the main diagnosis, of
diabetes or coronary artery disease (13). Later, strategies
for the complementary diagnostic investigation for each
case are suggested - so if the patient has DM 2 without
clinical evidence of CAD, an investigation of the pre-
s e n c eo fc o r o n a r ya r t e r yd i s e a s em u s tb ep e r f o r m e d
(electrocardiogram, echocardiogram, ergometric test
and, when indicated, ischemia-stimulating tests) in order
to find out if the patient originally had coronary artery
disease; on the other hand, if the patient had clinical
evidence of CAD, an investigation of the presence of
diabetes through fasting blood glucose, OGTT and gly-
cated haemoglobin is recommended [26].
The intensification of the concept of prevention of all
forms of dysglicaemia, which started in the early 1920s,
is currently recommended [27]. Several studies have
been done from 1997 to 2006 emphasizing this concept.
Some of them are: the Swedish Malmo Feasibility [28],
the Chinese DaQing Study [29], the Finnish Diabetes
Prevention (DPS) [30], the Diabetes Prevention Program
(DPP) [8], the Japanese Lifestyle Intervention Study [31],
the Study to Prevent Non-Insulin-Dependent Diabetes
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Diabetes (TRIPOD) [33], the Diabetes Reduction Assess-
ment with Ramipril and Rosiglitazone Medication
(DREAM) [34], among others. They reveal that treat-
ment through lifestyle changes (LSC) and/or drug treat-
ment decreases the conversion rate from pre-diabetic
into diabetic, but the best result in the above-mentioned
studies was observed with LSC.
In March 2007, the ADA proposed that all pre-dia-
betic patients would be recommended to undergo LSC;
however, if they have combined IGT and IFG or if they
are <60 years old or presented any related risk factors
such as BMI ≥ 35 kg/m
2, elevated triglycerides, reduced
HDL cholesterol, hypertension, family history of diabetes
and A1C >6%, metformin should be used concomitantly,
at the dosage of 850 mg bid [35].
Some considerations must be discussed concerning
the relationship between dysglicaemia and cardiovascu-
lar disease (CVD) and incident diabetes in developing
countries like Brazil.
So far we still need data to establish which is the best
predictor (fasting or post-load bood glucose or d
HbA1c) of the above -mentioned clinical conditions. All
these measures are related to different glycemic meta-
bolic process [1]. Another important point is the utility
of using these measures in clinical daily practice com-
paring to its use for epidemiological studies. The Aus-
tralian Diabetes, Obesity, and Lifestyle study has used
fasting and post-load glucose and HbA1c to predict
CVD and all-cause mortality and whether any of these
measures improved CVD and all-cause mortality beyond
that achieved by traditional risk factors [36]. The study
observed a linear relationship between post-load glucose
and HbA1c with all-cause and CVD mortality. Fasting
blood glucose showed J-shaped relationship. However
none of these measures significantly improved individual
risk identification over other traditional risk factors.
Another study, an observational one, with more than
40,000 members of Kaiser Permanente Northwest who
had fasting plasma glucose levels less than 100 mg/dL
showed an increase of diabetes risk of 6% for each mg/
dL of fasting blood glucose even after controlling for
other risk factors. Furthermore, increase BMI and trigly-
cerides levels, decrease HDL-cholesterol levels presence
of hypertension and smoking increase the risk of devel-
oping diabetes associated with normal fasting plasma
glucose. The most important conclusion that emerged
from this study was the possibility to identify high-risk
patients to be screened for diabetes, thus helping clini-
cians in daily clinical practice [37].
Considering the overall population in Brazil (near 200
millions), the growing prevalence of diabetes, pre-dia-
betes and obesity [38,39] as well as the estimated
increase in cardiovascular risk already observed in the
population with diabetes using the Framingham equa-
tion [40] is a matter of concern. These facts highlight
the importance of addressing health care and prevention
issues to the high-risk subjects. All these clinical condi-
tions must be treated intensively from its early stages.
Non-pharmacological and pharmacological treatments
must aim the goals for weight, glycaemic, blood pressure
and lipid control. Considering pre-diabetes as a clinical
entity, non-pharmacological treatment with diet and
exercise gave the best results with rates of prevention of
diabetes up to 60% and so must be emphasized. Phar-
macological treatments are indicated when we have fail-
ure to diet and exercise with drugs which have shown
clinical benefits related to reduction in morbidity and
mortality. However, there is still need for new long-term
studies to assess the real benefits of several therapeutical
approaches, as well as its cost effectiveness.
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